연구동향 분석
박사

골다공증에서 PRMT 단백질들의 병태생리학적 기능 연구와 응용 : The Pathophysiological Role of PRMT proteins in Osteoporosis and its Applications

최주희 2015년

논문상세정보
인용/피인용
' 골다공증에서 PRMT 단백질들의 병태생리학적 기능 연구와 응용 : The Pathophysiological Role of PRMT proteins in Osteoporosis and its Applications' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • osteoclastogenesis
  • osteoporosis
  • ovariectomized mice
  • prmt proteins
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
281 0

0.0%

' 골다공증에서 PRMT 단백질들의 병태생리학적 기능 연구와 응용 : The Pathophysiological Role of PRMT proteins in Osteoporosis and its Applications' 의 참고문헌

  • YIP, K. H., ZHENG, M. H., STEER, J. H., GIARDINA, T. M., HAN, R., LO, S. Z.,BAKKER, A. J., CASSADY, A. I., JOYCE, D. A. & XU, J. 2005. Thapsigarginmodulates osteoclastogenesis through the regulation of RANKL-induced signalingpathways and reactive oxygen species production. J Bone Miner Res, 20, 1462-71.
  • YANG, Y. & BEDFORD, M. T. 2013. Protein arginine methyltransferases and cancer. NatRev Cancer, 13, 37-50.
  • YANG, S.-H., SHARROCKS, A. D. & WHITMARSH, A. J. 2013. MAP kinase signallingcascades and transcriptional regulation. Gene, 513, 1-13.
  • YAGI, M., MIYAMOTO, T., SAWATANI, Y., IWAMOTO, K., HOSOGANE, N., FUJITA, N.,MORITA, K., NINOMIYA, K., SUZUKI, T., MIYAMOTO, K., OIKE, Y., TAKEYA,M., TOYAMA, Y. & SUDA, T. 2005. DC-STAMP is essential for cell-cell fusion inosteoclasts and foreign body giant cells. J Exp Med, 202, 345-51.
  • XU, X., WANG, H. J., MURPHY, P. A., COOK, L. & HENDRICH, S. 1994. Daidzein is amore bioavailable soymilk isoflavone than is genistein in adult women. J Nutr, 124,825-32.
  • WITT-ENDERBY, P. A., RADIO, N. M., DOCTOR, J. S. & DAVIS, V. L. 2006. Therapeutictreatments potentially mediated by melatonin receptors: potential clinical uses in theprevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res, 41, 297-305.
  • WITT-ENDERBY, P. A., BENNETT, J., JARZYNKA, M. J., FIRESTINE, S. & MELAN, M.A. 2003. Melatonin receptors and their regulation: biochemical and structuralmechanisms. Life Sci, 72, 2183-98.
  • WISEMAN, H. 2000. The therapeutic potential of phytoestrogens. Expert Opin InvestigDrugs, 9, 1829-40.
  • WENSEL, T. M., IRANIKHAH, M. M. & WILBORN, T. W. 2011. Effects of denosumab onbone mineral density and bone turnover in postmenopausal women. Pharmacotherapy,31, 510-23.
  • WANG, S. C., DOWHAN, D. H., ERIKSSON, N. A. & MUSCAT, G. E. 2012.CARM1/PRMT4 is necessary for the glycogen gene expression programme inskeletal muscle cells. Biochem J, 444, 323-31.
  • WANG, D., STRANDGAARD, S., IVERSEN, J. & WILCOX, C. S. 2009. Asymmetricdimethylarginine, oxidative stress, and vascular nitric oxide synthase in essentialhypertension. Am J Physiol Regul Integr Comp Physiol, 296, R195-200.
  • WADA, T., NAKASHIMA, T., HIROSHI, N. & PENNINGER, J. M. 2006. RANKL?RANKsignaling in osteoclastogenesis and bone disease. Trends in Molecular Medicine, 12,17-25.
  • VALCAVI, R., ZINI, M., MAESTRONI, G. J., CONTI, A. & PORTIOLI, I. 1993. Melatoninstimulates growth hormone secretion through pathways other than the growthhormone-releasing hormone. Clin Endocrinol (Oxf), 39, 193-9.
  • VAHLE, J. L., SATO, M., LONG, G. G., YOUNG, J. K., FRANCIS, P. C., ENGELHARDT,J. A., WESTMORE, M. S., LINDA, Y. & NOLD, J. B. 2002. Skeletal changes in ratsgiven daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol, 30, 312-21.
  • USLU, S., UYSAL, A., OKTEM, G., YURTSEVEN, M., TANYALCIN, T. & BASDEMIR,G. 2007. Constructive effect of exogenous melatonin against osteoporosis afterovariectomy in rats. Anal Quant Cytol Histol, 29, 317-25.
  • TYAGI, A. M., SRIVASTAVA, K., SHARAN, K., YADAV, D., MAURYA, R. & SINGH, D.2011. Daidzein prevents the increase in CD4+CD28null T cells and B lymphopoesisin ovariectomized mice: a key mechanism for anti-osteoclastogenic effect. PLoS One,6, e21216.
  • TSUCHIYA, Y. & NISHIDA, E. 2003. Mammalian cultured cells as a model system ofperipheral circadian clocks. J Biochem, 134, 785-90.
  • TANG, J., FRANKEL, A., COOK, R. J., KIM, S., PAIK, W. K., WILLIAMS, K. R.,CLARKE, S. & HERSCHMAN, H. R. 2000. PRMT1 is the predominant type Iprotein arginine methyltransferase in mammalian cells. J Biol Chem, 275, 7723-30.
  • TAKAHASHI, N., UDAGAWA, N., TANAKA, S. & SUDA, T. 2003. Generating murineosteoclasts from bone marrow. Methods Mol Med, 80, 129-44.
  • TAIN, Y. L., HSIEH, C. S., CHEN, C. C., SHEEN, J. M., LEE, C. T. & HUANG, L. T. 2010.Melatonin prevents increased asymmetric dimethylarginine in young rats with bileduct ligation. J Pineal Res, 48, 212-21.
  • SWIERCZ, R., CHENG, D., KIM, D. & BEDFORD, M. T. 2007. Ribosomal protein rpS2 ishypomethylated in PRMT3-deficient mice. J Biol Chem, 282, 16917-23.
  • SUZUKI, N., SOMEI, M., KITAMURA, K., REITER, R. J. & HATTORI, A. 2008. Novelbromomelatonin derivatives suppress osteoclastic activity and increase osteoblasticactivity: implications for the treatment of bone diseases. J Pineal Res, 44, 326-34.
  • SUNG-HEE, C., SANG-WON, C., YOUNG-SUN, C., HEE-JUNG, K., YOUN-HEE, P.,YONG-CHUL, B. & WON-JUNG, L. 2007. Effect of Ethanol Extract of SafflowerSeed on Bone Loss in Ovariectomized Rat. Food Science and Biotechnology, 16, 392-397.
  • SUNDARAM, K., NISHIMURA, R., SENN, J., YOUSSEF, R. F., LONDON, S. D. &REDDY, S. V. 2007. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res, 313, 168-78.
  • SRINIVASAN, S., KOENIGSTEIN, A., JOSEPH, J., SUN, L., KALYANARAMAN, B.,ZAIDI, M. & AVADHANI, N. G. 2010. Role of mitochondrial reactive oxygenspecies in osteoclast differentiation. Ann N Y Acad Sci, 1192, 245-52.
  • SOYSA, N. S. & ALLES, N. 2009. NF-kappaB functions in osteoclasts. Biochem BiophysRes Commun, 378, 1-5.
  • SONG-JA, B., SUN-MI, S., YUN-JA, P., JUN-YOUNG, L., EUN-JU, C. & SANG-WON, C.2002. Cytotoxicity of Phenolic Compounds Isolated from Seeds of Safflower(Carthamus tinctorius L.) on Cancer Cell Lines. Food Science and Biotechnology, 11,140-146.
  • SOARES, J. M., JR., MASANA, M. I., ERSAHIN, C. & DUBOCOVICH, M. L. 2003. Functional melatonin receptors in rat ovaries at various stages of the estrous cycle. JPharmacol Exp Ther, 306, 694-702.
  • SIDDIQI, M. H., SIDDIQI, M. Z., KANG, S., NOH, H. Y., AHN, S., SIMU, S. Y., AZIZ, M. A., SATHISHKUMAR, N., JIMENEZ PEREZ, Z. E. & YANG, D. C. 2015. Inhibitionof Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL,JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An In Silicoand In Vitro Study. Phytother Res.
  • SCHMID, H. A. 1993. Decreased melatonin biosynthesis, calcium flux, pineal glandcalcification and aging: a hypothetical framework. Gerontology, 39, 189-99.
  • SAVOIA, C., EBRAHIMIAN, T., LEMARIE, C. A., PARADIS, P., IGLARZ, M., AMIRI, F.,JAVESHGANI, D. & SCHIFFRIN, E. L. 2010. Countervailing vascular effects ofrosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clin Sci (Lond), 118, 583-92.
  • SATUE, M., RAMIS, J. M., DEL MAR ARRIERO, M. & MONJO, M. 2015. A new role for5-methoxytryptophol on bone cells function in vitro. J Cell Biochem, 116, 551-8.
  • SANCHEZ-BARCELO, E. J., MEDIAVILLA, M. D., TAN, D. X. & REITER, R. J. 2010.Scientific basis for the potential use of melatonin in bone diseases: osteoporosis andadolescent idiopathic scoliosis. J Osteoporos, 2010, 830231.
  • RUGGIERO, S. L., MEHROTRA, B., ROSENBERG, T. J. & ENGROFF, S. L. 2004.Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63cases. J Oral Maxillofac Surg, 62, 527-34.
  • ROTH, J. A., KIM, B. G., LIN, W. L. & CHO, M. I. 1999. Melatonin promotes osteoblastdifferentiation and bone formation. J Biol Chem, 274, 22041-7.
  • RODAN, G. A. & MARTIN, T. J. 1981. Role of osteoblasts in hormonal control of boneresorption--a hypothesis. Calcif Tissue Int, 33, 349-51.
  • RIIS, B. J., HANSEN, M. A., JENSEN, A. M., OVERGAARD, K. & CHRISTIANSEN, C.1996. Low bone mass and fast rate of bone loss at menopause: Equal risk factors forfuture fracture: A 15-year follow-up Study. Bone, 19, 9-12.
  • REPPERT, S. M., WEAVER, D. R. & EBISAWA, T. 1994. Cloning and characterization of amammalian melatonin receptor that mediates reproductive and circadian responses.Neuron, 13, 1177-85.
  • PICHERIT, C., COXAM, V., BENNETAU-PELISSERO, C., KATI-COULIBALY, S.,DAVICCO, M. J., LEBECQUE, P. & BARLET, J. P. 2000. Daidzein is more efficientthan genistein in preventing ovariectomy-induced bone loss in rats. J Nutr, 130, 1675-81.
  • PHAN, T. C., XU, J. & ZHENG, M. H. 2004. Interaction between osteoblast and osteoclast:impact in bone disease. Histol Histopathol, 19, 1325-44.
  • PARK, M. J., KIM, D. I., CHOI, J. H., HEO, Y. R. & PARK, S. H. 2015. New role of irisin inhepatocytes: The protective effect of hepatic steatosis in vitro. Cell Signal, 27, 1831-1839.
  • PARK, K. H., KANG, J. W., LEE, E. M., KIM, J. S., RHEE, Y. H., KIM, M., JEONG, S. J.,PARK, Y. G. & KIM, S. H. 2011. Melatonin promotes osteoblastic differentiationthrough the BMP/ERK/Wnt signaling pathways. J Pineal Res, 51, 187-94.
  • PARADIES, G., PETROSILLO, G., PARADIES, V., REITER, R. J. & RUGGIERO, F. M.2010. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. JPineal Res, 48, 297-310.
  • OUYANG, Z., ZHAI, Z., LI, H., LIU, X., QU, X., LI, X., FAN, Q., TANG, T., QIN, A. &DAI, K. 2014. Hypericin suppresses osteoclast formation and wear particle-inducedosteolysis via modulating ERK signalling pathway. Biochem Pharmacol, 90, 276-87.
  • OSTROWSKA, Z., KOS-KUDLA, B., NOWAK, M., SWIETOCHOWSKA, E., MAREK, B.,GORSKI, J., KAJDANIUK, D. & WOLKOWSKA, K. 2003. The relationshipbetween bone metabolism, melatonin and other hormones in sham-operated andpinealectomized rats. Endocr Regul, 37, 211-24.
  • OSADA, S., SUZUKI, S., YOSHIMI, C., MATSUMOTO, M., SHIRAI, T., TAKAHASHI, S.& IMAGAWA, M. 2013. Elevated expression of coactivator-associated argininemethyltransferase 1 is associated with early hepatocarcinogenesis. Oncol Rep, 30,1669-74.
  • OKTEM, G., USLU, S., VATANSEVER, S. H., AKTUG, H., YURTSEVEN, M. E. &UYSAL, A. 2006. Evaluation of the relationship between inducible nitric oxidesynthase (iNOS) activity and effects of melatonin in experimental osteoporosis in therat. Surg Radiol Anat, 28, 157-62.
  • O'BRIEN, C. A. 2010. Control of RANKL gene expression. Bone, 46, 911-9.
  • NIH CONSENSUS DEVELOPMENT PANEL ON OSTEOPOROSIS PREVENTION, D.,AND THERAPY 2001. Osteoporosis prevention, diagnosis, and therapy. Jama, 285,785-95.
  • NAKASHIMA, T. & TAKAYANAGI, H. 2011. New regulation mechanisms of osteoclastdifferentiation. Ann N Y Acad Sci, 1240, E13-8.
  • MORALES, Y., NITZEL, D. V., PRICE, O. M., GUI, S., LI, J., QU, J. & HEVEL, J. M. 2015.Redox Control of Protein Arginine Methyltransferase 1 (PRMT1) Activity. J BiolChem, 290, 14915-26.
  • MIYAZAKI, T., KATAGIRI, H., KANEGAE, Y., TAKAYANAGI, H., SAWADA, Y.,YAMAMOTO, A., PANDO, M. P., ASANO, T., VERMA, I. M., ODA, H.,NAKAMURA, K. & TANAKA, S. 2000. Reciprocal role of ERK and NF-kappaBpathways in survival and activation of osteoclasts. J Cell Biol, 148, 333-42.
  • MINE, Y., MAKIHIRA, S., YAMAGUCHI, Y., TANAKA, H. & NIKAWA, H. 2014.Involvement of ERK and p38 MAPK pathways on Interleukin-33-induced RANKLexpression in osteoblastic cells. Cell Biol Int, 38, 655-62.
  • MCNAMARA, L. M. 2010. Perspective on post-menopausal osteoporosis: establishing aninterdisciplinary understanding of the sequence of events from the molecular level towhole bone fractures. J R Soc Interface, 7, 353-72.
  • MCHUGH, K. P., HODIVALA-DILKE, K., ZHENG, M. H., NAMBA, N., LAM, J.,NOVACK, D., FENG, X., ROSS, F. P., HYNES, R. O. & TEITELBAUM, S. L. 2000. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. JClin Invest, 105, 433-40.
  • MATTHAUS, B., OZCAN, M. M. & AL JUHAIMI, F. Y. 2015. Fatty acid composition andtocopherol profiles of safflower (Carthamus tinctorius L.) seed oils. Nat Prod Res, 29,193-6.
  • MATSUMOTO, M., SUDO, T., MARUYAMA, M., OSADA, H. & TSUJIMOTO, M. 2000.Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesisinduced by tumor necrosis factor. FEBS Lett, 486, 23-8.
  • MA, X., LIU, Y., ZHANG, Y., YU, X., WANG, W. & ZHAO, D. 2014. Jolkinolide B inhibits１３６RANKL-induced osteoclastogenesis by suppressing the activation NF-kappaB andMAPK signaling pathways. Biochem Biophys Res Commun, 445, 282-8.
  • LU, R., HU, C. P., WU, X. P., LIAO, E. Y. & LI, Y. J. 2002. Effect of age on bone mineraldensity and the serum concentration of endogenous nitric oxide synthase inhibitors inrats. Comp Med, 52, 224-8.
  • LORENTZON, M. 2015. Osteoporosis: the evolution of a diagnosis. J Intern Med, 277, 650-61.
  • LITOVKA, I. H., MAZEPA-KRYZHANIVS'KA, Y. O. & BEREZOVSKYI, V. 2014. [Theeffect of melatonin on bone tissue metabolism]. Fiziol Zh, 60, 102-9.
  • LINDSAY, R., HART, D. M. & CLARK, D. M. 1984. The minimum effective dose ofestrogen for prevention of postmenopausal bone loss. Obstet Gynecol, 63, 759-63.
  • LIN, P.-Y. & LAI, H.-M. 2006. Bioactive Compounds in Legumes and Their GerminatedProducts. Journal of Agricultural and Food Chemistry, 54, 3807-3814.
  • LIM, S. K., JEONG, Y. W., KIM, D. I., PARK, M. J., CHOI, J. H., KIM, S. U., KANG, S. S.,HAN, H. J. & PARK, S. H. 2013. Activation of PRMT1 and PRMT5 mediateshypoxia- and ischemia-induced apoptosis in human lung epithelial cells and the lungof miniature pigs: the role of p38 and JNK mitogen-activated protein kinases. Biochem Biophys Res Commun, 440, 707-13.
  • LELOVAS, P. P., XANTHOS, T. T., THOMA, S. E., LYRITIS, G. P. & DONTAS, I. A. 2008.The laboratory rat as an animal model for osteoporosis research. Comp Med, 58, 424-30.
  • LEIBBRANDT, A. & PENNINGER, J. M. 2008. RANK/RANKL: regulators of immuneresponses and bone physiology. Ann N Y Acad Sci, 1143, 123-50.
  • LEE, Z. H. & KIM, H. H. 2003. Signal transduction by receptor activator of nuclear factorkappa B in osteoclasts. Biochem Biophys Res Commun, 305, 211-4.
  • LEE, S. W., HAN, S. I., KIM, H. H. & LEE, Z. H. 2002. TAK1-dependent activation of AP-1and c-Jun N-terminal kinase by receptor activator of NF-kappaB. J Biochem Mol Biol,35, 371-6.
  • LEE, S. H., DING, Y., YAN, X. T., KIM, Y. H. & JANG, H. D. 2013. Scopoletin and scopolinisolated from Artemisia iwayomogi suppress differentiation of osteoclasticmacrophage RAW 264.7 cells by scavenging reactive oxygen species. J Nat Prod, 76,615-20.
  • LEE, N. K., CHOI, Y. G., BAIK, J. Y., HAN, S. Y., JEONG, D. W., BAE, Y. S., KIM, N. &LEE, S. Y. 2005. A crucial role for reactive oxygen species in RANKL-inducedosteoclast differentiation. Blood, 106, 852-9.
  • LEE, H.-Y., PARK, S.-H., CHAE, S.-W., SOUNG, N.-K., OH, M.-J., KIM, J. S., KIM, Y. O.& CHAE, H.-J. 2015. Aqueous ginseng extract has a preventive role in RANKLinducedosteoclast differentiation and estrogen deficiency-induced osteoporosis. Journal of Functional Foods, 13, 192-203.
  • LAMBETH, J. D. 2004. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol,4, 181-9.
  • LALEMAN, W., OMASTA, A., VAN DE CASTEELE, M., ZEEGERS, M., VANDER ELST,I., VAN LANDEGHEM, L., SEVERI, T., VAN PELT, J., ROSKAMS, T., FEVERY, J.& NEVENS, F. 2005. A role for asymmetric dimethylarginine in the pathophysiologyof portal hypertension in rats with biliary cirrhosis. Hepatology, 42, 1382-90.
  • KWAN TAT, S., PADRINES, M., THEOLEYRE, S., HEYMANN, D. & FORTUN, Y. 2004.IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.Cytokine Growth Factor Rev, 15, 49-60.
  • KWAK, H. B., LEE, B. K., OH, J., YEON, J. T., CHOI, S. W., CHO, H. J., LEE, M. S., KIM,J. J., BAE, J. M., KIM, S. H. & KIM, H. S. 2010. Inhibition of osteoclastdifferentiation and bone resorption by rotenone, through down-regulation of RANKLinducedc-Fos and NFATc1 expression. Bone, 46, 724-31.
  • KING, R. A. 1998. Daidzein conjugates are more bioavailable than genistein conjugates inrats. Am J Clin Nutr, 68, 1496s-1499s.
  • KIM, K., KIM, J. H., LEE, J., JIN, H. M., LEE, S. H., FISHER, D. E., KOOK, H., KIM, K. K., CHOI, Y. & KIM, N. 2005. Nuclear factor of activated T cells c1 inducesosteoclast-associated receptor gene expression during tumor necrosis factor-relatedactivation-induced cytokine-mediated osteoclastogenesis. J Biol Chem, 280, 35209-16.
  • KIM, H. S., SUH, K. S., SUL, D., KIM, B. J., LEE, S. K. & JUNG, W. W. 2012. Theinhibitory effect and the molecular mechanism of glabridin on RANKL-inducedosteoclastogenesis in RAW264.7 cells. Int J Mol Med, 29, 169-77.
  • KIM, H. J., BAE, Y. C., PARK, R. W., CHOI, S. W., CHO, S. H., CHOI, Y. S. & LEE, W. J. 2002. Bone-protecting effect of safflower seeds in ovariectomized rats. Calcif TissueInt, 71, 88-94.
  • KIM, E.-O. O. J.-H. L. S.-K. L. J.-Y. C. S.-W. 2007. Antioxidant Properties andQuantification of Phenolic Compounds from Safflower (Carthamus tinctorius L.)Seeds. Food Science and Biotechnology, 16, 71-77.
  • KIM, D. I., PARK, M. J., LIM, S. K., PARK, J. I., YOON, K. C., HAN, H. J.,GUSTAFSSON, J. A., LIM, J. H. & PARK, S. H. 2015. PRMT3 regulates hepaticlipogenesis through direct interaction with LXRalpha. Diabetes, 64, 60-71.
  • KIM, D. I., PARK, M. J., LIM, S. K., CHOI, J. H., KIM, J. C., HAN, H. J., KUNDU, T. K.,PARK, J. I., YOON, K. C., PARK, S. W., PARK, J. S., HEO, Y. R. & PARK, S. H. 2014. High-glucose-induced CARM1 expression regulates apoptosis of human retinalpigment epithelial cells via histone 3 arginine 17 dimethylation: role in diabeticretinopathy. Arch Biochem Biophys, 560, 36-43.
  • KEMENY-BEKE, A., GESZTELYI, R., BODNAR, N., ZSUGA, J., KEREKES, G., ZSUGA,M., BIRI, B., KEKI, S., SZODORAY, P., BERTA, A., SZEKANECZ, Z. & SZANTO,S. 2011. Increased production of asymmetric dimethylarginine (ADMA) inankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine, 78, 184-7.
  • KARSENTY, G. 2003. The complexities of skeletal biology. Nature, 423, 316-8.
  • KANIS, J. A. 2002. Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359,1929-36.
  • KANAZAWA, I., YANO, S., YAMAGUCHI, T., NOTSU, Y., NABIKA, T. & SUGIMOTO, T.2010. Relationships between dimethylarginine and the presence of vertebral fracturesin type 2 diabetes mellitus. Clin Endocrinol (Oxf), 73, 463-8.
  • JUN-HAN, K., SEON-MIN, J., MI-YOUNG, A., SAE-KWANG, K., JAE-HYUN, L.,MYUNG-SOOK, C. & KWANG-DEOG, M. 1998. Effects of Diet of KoreanSafflower(Carthamus tinctorious L.) Seed Powder on Bone Tissue in Rats during theRecovery of Rib Fracture. JOURNAL OF THE KOREAN SOCIETY OF FOODSCIENCE AND NUTRITION, 27, 698-704.
  • JOHNELL, O. & KANIS, J. A. 2006. An estimate of the worldwide prevalence and disabilityassociated with osteoporotic fractures. Osteoporos Int, 17, 1726-33.
  • JANG, H. O., PARK, Y. S., LEE, J. H., SEO, J. B., KOO, K. I., JEONG, S. C., JIN, S. D.,LEE, Y. H., EOM, H. S. & YUN, I. 2007. Effect of extracts from safflower seeds onosteoblast differentiation and intracellular calcium ion concentration in MC3T3-E1cells. Nat Prod Res, 21, 787-97.
  • IOTSOVA, V., CAAMANO, J., LOY, J., YANG, Y., LEWIN, A. & BRAVO, R. 1997.Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med, 3, 1285-9.
  • INAMITSU, M., ITOH, S., HELLMAN, U., TEN DIJKE, P. & KATO, M. 2006. Methylationof Smad6 by protein arginine N-methyltransferase 1. FEBS Lett, 580, 6603-11.
  • IKEDA, F., NISHIMURA, R., MATSUBARA, T., TANAKA, S., INOUE, J., REDDY, S. V.,HATA, K., YAMASHITA, K., HIRAGA, T., WATANABE, T., KUKITA, T.,YOSHIOKA, K., RAO, A. & YONEDA, T. 2004. Critical roles of c-Jun signaling inregulation of NFAT family and RANKL-regulated osteoclast differentiation. J ClinInvest, 114, 475-84.
  • IBERG, A. N., ESPEJO, A., CHENG, D., KIM, D., MICHAUD-LEVESQUE, J., RICHARD,S. & BEDFORD, M. T. 2008. Arginine methylation of the histone H3 tail impedeseffector binding. J Biol Chem, 283, 3006-10.
  • HIRAMATSU, M., TAKAHASHI, T., KOMATSU, M., KIDO, T. & KASAHARA, Y. 2009.Antioxidant and neuroprotective activities of Mogami-benibana (safflower,Carthamus tinctorius Linne). Neurochem Res, 34, 795-805.
  • HERRMANN, F., PABLY, P., ECKERICH, C., BEDFORD, M. T. & FACKELMAYER, F. O.2009. Human protein arginine methyltransferases in vivo--distinct properties of eightcanonical members of the PRMT family. J Cell Sci, 122, 667-77.
  • HASSA, P. O., COVIC, M., BEDFORD, M. T. & HOTTIGER, M. O. 2008. Protein argininemethyltransferase 1 coactivates NF-kappaB-dependent gene expressionsynergistically with CARM1 and PARP1. J Mol Biol, 377, 668-78.
  • HARRIS, S. T., WATTS, N. B., GENANT, H. K. & ET AL. 1999. Effects of risedronatetreatment on vertebral and nonvertebral fractures in women with postmenopausalosteoporosis: A randomized controlled trial. JAMA, 282, 1344-1352.
  • GORDON, N. 2000. The therapeutics of melatonin: a paediatric perspective. Brain Dev, 22,213-7.
  • GA-HWA, K., EUN-JU, C. & SANG-WON, C. 1999. Antioxidative Activity of PhenolicCompounds in Roasted Safflower (Carthamus tinctorius L.) Seeds. PreventiveNutrition and Food Science, 4, 221-225.
  • FULLER, K., LAWRENCE, K. M., ROSS, J. L., GRABOWSKA, U. B., SHIROO, M.,SAMUELSSON, B. & CHAMBERS, T. J. 2008. Cathepsin K inhibitors preventmatrix-derived growth factor degradation by human osteoclasts. Bone, 42, 200-11.
  • FU, S. W., ZENG, G. F., ZONG, S. H., ZHANG, Z. Y., ZOU, B., FANG, Y., LU, L. & XIAO,D. Q. 2014. Systematic review and meta-analysis of the bone protective effect ofphytoestrogens on osteoporosis in ovariectomized rats. Nutr Res, 34, 467-77.
  • FRASER, L. A., VOGT, K. N., ADACHI, J. D. & THABANE, L. 2011. Fracture riskassociated with continuation versus discontinuation of bisphosphonates after 5 yearsof therapy in patients with primary osteoporosis: a systematic review and metaanalysis. Ther Clin Risk Manag, 7, 157-66.
  • FRANZOSO, G., CARLSON, L., XING, L., POLJAK, L., SHORES, E. W., BROWN, K. D.,LEONARDI, A., TRAN, T., BOYCE, B. F. & SIEBENLIST, U. 1997. Requirementfor NF-kappaB in osteoclast and B-cell development. Genes Dev, 11, 3482-96.
  • FACCIO, R., NOVACK, D. V., ZALLONE, A., ROSS, F. P. & TEITELBAUM, S. L. 2003.Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cellattachment are controlled by beta3 integrin. J Cell Biol, 162, 499-509.
  • EUN OK, K., KI TEAK, L. & SANG WON, C. 2008. Chemical Comparison of GerminatedandUngerminated-Safflower (Carthamus tinctorius) Seeds. JOURNAL OF THEKOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION, 37, 1162-1167.
  • DELAGRANGE, P., ATKINSON, J., BOUTIN, J. A., CASTEILLA, L., LESIEUR, D.,MISSLIN, R., PELLISSIER, S., PENICAUD, L. & RENARD, P. 2003. Therapeuticperspectives for melatonin agonists and antagonists. J Neuroendocrinol, 15, 442-8.
  • DARNAY, B. G., HARIDAS, V., NI, J., MOORE, P. A. & AGGARWAL, B. B. 1998.Characterization of the intracellular domain of receptor activator of NF-kappaB(RANK). Interaction with tumor necrosis factor receptor-associated factors andactivation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem, 273, 20551-5.
  • CHOI, D., OH, K. J., HAN, H. S., YOON, Y. S., JUNG, C. Y., KIM, S. T. & KOO, S. H.2012. Protein arginine methyltransferase 1 regulates hepatic glucose production in aFoxO1-dependent manner. Hepatology, 56, 1546-56.
  • CHO, S. H., JANG, J. H., YOON, J. Y., HAN, C. D., CHOI, Y. & CHOI, S. W. 2011. Effectsof a safflower tea supplement on antioxidative status and bone markers inpostmenopausal women. Nutr Res Pract, 5, 20-7.
  • CHEN, Y., XU, X., SHENG, M., ZHANG, X., GU, Q. & ZHENG, Z. 2009. PRMT-1 andDDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediateddiabetic retinopathy. Experimental Eye Research, 89, 1028-1034.
  • CHEN, D., MA, H., HONG, H., KOH, S. S., HUANG, S. M., SCHURTER, B. T., ASWAD,D. W. & STALLCUP, M. R. 1999. Regulation of transcription by a proteinmethyltransferase. Science, 284, 2174-7.
  • CHANG, K. L., HU, Y. C., HSIEH, B. S., CHENG, H. L., HSU, H. W., HUANG, L. W. &SU, S. J. 2013. Combined effect of soy isoflavones and vitamin D3 on bone loss inovariectomized rats. Nutrition, 29, 250-7.
  • CARDINALI, D. P., LADIZESKY, M. G., BOGGIO, V., CUTRERA, R. A. & MAUTALEN,C. 2003. Melatonin effects on bone: experimental facts and clinical perspectives. JPineal Res, 34, 81-7.
  • BUBENIK, G. A. 2002. Gastrointestinal melatonin: localization, function, and clinicalrelevance. Dig Dis Sci, 47, 2336-48.
  • BRUNI, O., ALONSO-ALCONADA, D., BESAG, F., BIRAN, V., BRAAM, W., CORTESE,S., MOAVERO, R., PARISI, P., SMITS, M., VAN DER HEIJDEN, K. &CURATOLO, P. 2015. Current role of melatonin in pediatric neurology: clinicalrecommendations. Eur J Paediatr Neurol, 19, 122-33.
  • BOYLE, W. J., SIMONET, W. S. & LACEY, D. L. 2003. Osteoclast differentiation andactivation. Nature, 423, 337-42.
  • BOONEN, S., ROSENBERG, E., CLAESSENS, F., VANDERSCHUEREN, D. &PAPAPOULOS, S. 2012. Inhibition of cathepsin K for treatment of osteoporosis. CurrOsteoporos Rep, 10, 73-9.
  • BOHM, C., HAYER, S., KILIAN, A., ZAISS, M. M., FINGER, S., HESS, A., ENGELKE, K.,KOLLIAS, G., KRONKE, G., ZWERINA, J., SCHETT, G. & DAVID, J. P. 2009. Thealpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol, 183,5938-47.
  • BOGER, R. H. 2006. Asymmetric dimethylarginine (ADMA): a novel risk marker incardiovascular medicine and beyond. Ann Med, 38, 126-36.
  • BITTO, A., POLITO, F., SQUADRITO, F., MARINI, H., D'ANNA, R., IRRERA, N.,MINUTOLI, L., GRANESE, R. & ALTAVILLA, D. 2010. Genistein aglycone: a dualmode of action anti-osteoporotic soy isoflavone rebalancing bone turnover towardsbone formation. Curr Med Chem, 17, 3007-18.
  • BELTOWSKI, J. & KEDRA, A. 2006. Asymmetric dimethylarginine (ADMA) as a target forpharmacotherapy. Pharmacol Rep, 58, 159-78.
  • BAYLIS, C. 2008. Nitric oxide deficiency in chronic kidney disease. Am J Physiol RenalPhysiol, 294, F1-9.
  • ASAGIRI, M., SATO, K., USAMI, T., OCHI, S., NISHINA, H., YOSHIDA, H., MORITA, I.,WAGNER, E. F., MAK, T. W., SERFLING, E. & TAKAYANAGI, H. 2005.Autoamplification of NFATc1 expression determines its essential role in bonehomeostasis. J Exp Med, 202, 1261-9.
  • ARAI, F., MIYAMOTO, T., OHNEDA, O., INADA, T., SUDO, T., BRASEL, K., MIYATA,T., ANDERSON, D. M. & SUDA, T. 1999. Commitment and differentiation ofosteoclast precursor cells by the sequential expression of c-Fms and receptor activatorof nuclear factor kappaB (RANK) receptors. J Exp Med, 190, 1741-54.
  • ANG, E., LIU, Q., QI, M., LIU, H. G., YANG, X., CHEN, H., ZHENG, M. H. & XU, J. 2011.Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-inducedactivation of NF-kappaB and ERK. J Cell Biochem, 112, 89-97.
  • ANDERSON, G. L., LIMACHER, M., ASSAF, A. R., BASSFORD, T., BERESFORD, S. A.,BLACK, H., BONDS, D., BRUNNER, R., BRZYSKI, R., CAAN, B.,CHLEBOWSKI, R., CURB, D., GASS, M., HAYS, J., HEISS, G., HENDRIX, S.,HOWARD, B. V., HSIA, J., HUBBELL, A., JACKSON, R., JOHNSON, K. C., JUDD,H., KOTCHEN, J. M., KULLER, L., LACROIX, A. Z., LANE, D., LANGER, R. D.,LASSER, N., LEWIS, C. E., MANSON, J., MARGOLIS, K., OCKENE, J.,O'SULLIVAN, M. J., PHILLIPS, L., PRENTICE, R. L., RITENBAUGH, C.,ROBBINS, J., ROSSOUW, J. E., SARTO, G., STEFANICK, M. L., VAN HORN, L.,WACTAWSKI-WENDE, J., WALLACE, R. & WASSERTHEIL-SMOLLER, S. 2004. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy:the Women's Health Initiative randomized controlled trial. Jama, 291, 1701-12.
  • AN, W., KIM, J. & ROEDER, R. G. 2004. Ordered cooperative functions of PRMT1, p300,and CARM1 in transcriptional activation by p53. Cell, 117, 735-48.
  • ALAM, M. R., KIM, S. M., LEE, J. I., CHON, S. K., CHOI, S. J., CHOI, I. H. & KIM, N. S.2006. Effects of Safflower seed oil in osteoporosis induced-ovariectomized rats. Am JChin Med, 34, 601-12.
  • ACUNA-CASTROVIEJO, D., ESCAMES, G., VENEGAS, C., DIAZ-CASADO, M. E.,LIMA-CABELLO, E., LOPEZ, L. C., ROSALES-CORRAL, S., TAN, D. X. &REITER, R. J. 2014. Extrapineal melatonin: sources, regulation, and potentialfunctions. Cell Mol Life Sci, 71, 2997-3025.